Completed PHASE3 INTERVENTIONAL NCT00122304

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

Safety in Hemolytic PNH Patients Treated With Eculizumab: a Multi-Center Open-Label Research Design Study

Sponsor: Alexion Pharmaceuticals, Inc.

Interventions eculizumab

Updated 8 times since 2017 Last updated: Feb 20, 2007 Started: Dec 31, 2004 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hemoglobinuria, Paroxysmal and is currently completed. Alexion Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2023 — Jul 2024 [monthly]

Completed PHASE3
Apr 2023 — Dec 2023 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jan 2021 — Apr 2023 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Barcelona, Spain , Basel, Switzerland , Bethesda, United States , Boston, United States , Brussels, Belgium , Buffalo, United States , Cleveland, United States , Dublin, Ireland , Durham, United States and 36 more locations